The Latest Malaria News, in 60 Seconds.

Researchers detail the role of PI(3)P in preventing heat-shock-induced cell death and the BK-SE36 adjuvanted malaria vaccine is found to be safe, well-tolerated and protective in clinical trials.

Malaria Minute on iTunes and Spotify


Transcript:

Over the course of its lifecycle, Plasmodium falciparum malaria parasites are exposed to different environmental pressures, for example, the high temperatures during the fever episode of human blood-stage infection. Researchers have now found that a particular phosphate – phosphatidylinositol 3-phosphate, or PI(3)P, stabilises the digestive vacuole of the parasite preventing heat-shock-induced cell death. Researchers found that PI(3)P-deficient parasites are not able to cope with the fever’s heat and that a PI3P-binding protein, PfHsp70, is also critical for parasite survival under heat stress.

The results are in from a Phase 1a clinical trial of the adjuvanted malaria vaccine, BK-SE36. The trial involved 26 malaria-naive adults and found that the vaccine is safe, well-tolerated and, when given in two doses 21 days apart, offers great protection.

Sources:

Phosphatidylinositol 3-phosphate and Hsp70 Protect Plasmodium falciparum From Heat-Induced Cell Death

First-in-Human Randomised Trial and Follow-up Study of Plasmodium falciparum Blood-Stage Malaria Vaccine BK-SE36 with CpG-ODN(K3)


Image Credits: CDC/ Dr. Mae Melvin [17368]

Scientific Advisor: Elena Gómez-Díaz, Institute of Parasitology and Biomedicine, Spain

Print Friendly, PDF & Email
Categories: Malaria Minute

Stay Informed

Keep up to date with the latest malaria news.